{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"205"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"10"}]}],"title":"Engrafted"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Primary Graft Failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"title":"Late graft failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Not Evaluable Engraftment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"groups":[{"description":"Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)\n\ntotal body irradiation: dose of 1375-1500 cGy\n\nThiotepa: 5 mg/kg/day x 2 or 10 mg/kg/day x 1\n\nCyclophosphamide: 60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"OG000","title":"Total Body Irradiation, Thiotepa and Cyclophosphamide"},{"description":"Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)\n\nBusulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics\n\nMelphalan: 70mg/m2/day x 2\n\nFludarabine: 25mg/m2/ day x 5\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"OG001","title":"Busulfan, Melphalan and Fludarabine"},{"description":"Clofarabine (20mg/m2/ day x 5) (or, for children \\<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)\n\nThiotepa: 5 mg/kg/day x 2 or 10 mg/kg/day x 1\n\nMelphalan: 70mg/m2/day x 2\n\nClofarabine: 20mg/m2/ day x 5 (or, for children \\<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"OG002","title":"Clofarabine, Melphalan and Thiotepa"},{"description":"Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)\n\nThiotepa: 5 mg/kg/day x 2 or 10 mg/kg/day x 1\n\nMelphalan: 70mg/m2/day x 2\n\n(CliniMACS) T-cell depleted PBSC Transplant","id":"OG003","title":"Melphalan, Fludarabine and Thiotepa"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Please note 13 participants were not evaluated in the data set as they received a second or third HCT on protocol.","reportingStatus":"POSTED","timeFrame":"3 years","title":"The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease Targeted Cytoreduction Regimens.","type":"PRIMARY","unitOfMeasure":"Participants"}